# Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)

> **NCT05399485** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 496 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Rimegepant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05399485
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-09
- **Primary completion:** 2024-01-18
- **Final completion:** 2024-11-07
- **Target enrollment:** 496 (ACTUAL)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05399485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05399485, "Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05399485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*